Organoid Individualized Drug Sensitivity Detection (Beixin An)

Clinical service for personalized cancer drug response evaluation using patient-derived tumor organoids and organ chips. Supports precision medicine treatment selection and optimization.

A high-throughput drug sensitivity testing platform utilizing renewable primary cancer cells to predict treatment response. This service enables personalized treatment selection through comprehensive chemotherapy and targeted drug profiling.

Precision medicine test identifying optimal chemotherapy agents for individual tumors based on molecular characteristics. Guides targeted drug selection and improves treatment efficacy.

A service that establishes three-dimensional in vitro cell culture models from patient-derived fresh tumor tissue, creating stereoscopic models with high similarity to patient tumor characteristics. Tumor organoids maintain high consistency with patient tumor pathological, molecular, drug sensitivity, and genetic stability features, and can be cultured long-term and stably passaged in vitro. This organoid model has been recommended for clinical guidance of personalized medication therapy, with reported accuracy reaching 80%.

A predictive test for personalization of anti-tumor treatment. This diagnostic tool is designed to assist in tailoring cancer treatment strategies to individual patient needs.

A targeted blood-based early detection service for specific cancer types utilizing gene methylation biomarkers. This clinical testing service is performed by BioChain's certified medical laboratory.

Software medical device that analyzes Raman signal patterns of exosomes using artificial intelligence technology to diagnose diseases. It requires only 500 µL of blood sample and provides diagnostic results within one hour for multiple cancer types simultaneously.

A portable diagnostic test kit for detecting occult blood, designed for early cancer screening in digestive tract-related conditions. The product received Class II medical device registration certification from Shandong Province Drug Supervision and Management Bureau. It is manufactured by Lixin Nuo Kang, a wholly-owned subsidiary of Linaxin Biotechnology, and represents the company's technological capabilities in in vitro diagnostics for home-based early cancer screening.

Comprehensive cancer drug resistance diagnostic platform providing insights into treatment resistance mechanisms. Guides clinical decision-making for resistant cancer cases.

A cancer diagnosis platform product utilizing GeneCker's ultra-precision CRISPR/Cas9 technology for standardization of liquid biopsy diagnosis. Integrates sample collection, DNA sequencing via NGS or Sanger sequencing methods, and provides results in result booklet or PDF format.

In vitro diagnostic devices for oncology applications focusing on genetic mutation detection and biomarker analysis. Supports clinical decision-making through comprehensive molecular profiling.

Comprehensive diagnostic solutions for cancer detection and treatment monitoring utilizing FISH and circulating tumor cell (CTC) detection technology. These solutions enable personalized medicine approaches and targeted therapy delivery.